Skip to content
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
You are currently viewing Brexit Britain becomes unlikely psychedelic haven as Albert Labs IPOs

Brexit Britain becomes unlikely psychedelic haven as Albert Labs IPOs

  • Post author:Olly PP
  • Post published:March 10, 2022
  • Post category:Industry News
Tags: Industry Media

Read more articles

Previous PostPersisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees
Next PostIs the UK Becoming a Global Center for Psychedelic Medicine?

You Might Also Like

Read more about the article Can Psychedelics Cure?

Can Psychedelics Cure?

October 22, 2022
Read more about the article We cannot meet the mental health needs of cancer patients without breaking down silos

We cannot meet the mental health needs of cancer patients without breaking down silos

April 29, 2022
Read more about the article Psilocybin-Assisted Psychotherapy Treatment with Alcohol Use Disorder: A Randomized Clinical Trial

Psilocybin-Assisted Psychotherapy Treatment with Alcohol Use Disorder: A Randomized Clinical Trial

August 24, 2022

Recent Posts

  • Expansion of Drug Discovery and a Promising Pipeline
  • Albert Labs Announces Private Placement
  • Letter of Intent (LOI) for First-In-Human studies with iNGENū CRO
  • Albert Labs Provides Corporate Update
  • Psychedelic Therapy isn’t Fringe Anymore

Recent Comments

    Innovative mental health medicines for patients with unmet needs

    • Legal Disclaimer
    • Privacy Policy
    • Modern Slavery Statement
    • Cookie Policy
    • Legal Disclaimer
    • Privacy Policy
    • Modern Slavery Statement
    • Cookie Policy

    © 2022 Albert Labs. All Rights Reserved

    • About
    • Team
    • Clinical Trials
    • KRN-101
    • Investing
    • Press & Updates
    • Contact
    • About
    • Team
    • Clinical Trials
    • KRN-101
    • Investing
    • Press & Updates
    • Contact
    Twitter Linkedin Youtube Envelope
    CSE:ABRT
    FSE: VB50
    CSE:ABRT
    FSE: VB50

    About Albert Labs

    We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

    If you would like support or more information around making an investment, please contact investing@albertlabs.com

    Twitter Linkedin Youtube Envelope

    Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

    • This field is for validation purposes and should be left unchanged.

    Twitter
    Youtube
    Linkedin
    Instagram
    Envelope
    Twitter
    Youtube
    Linkedin
    Instagram
    Envelope

    By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok